Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05658640 Phase 1, Phase 2
Recruiting
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapse...
Condition
Acute Lymphoblastic Leukemia, in Relapse
Enrollment
26 pts
Location
Austria, Belgium, Denmark
Sponsor
Princess Maxima Center for Ped
NCT07318818 Phase 1, Phase 2
Recruiting
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Condition
Recurrent Glioblastoma IDH Wildtype
Enrollment
26 pts
Location
China
Sponsor
Tasly Pharmaceutical Group Co.
NCT07739511 Phase 1, Phase 2
Recruiting
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A D...
Condition
HER2 + Breast Cancer
Enrollment
30 pts
Location
China
Sponsor
Liu Shu
NCT06820164 Phase 1, Phase 2
Recruiting
Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride
Condition
Lipoma
Enrollment
20 pts
Location
United States
Sponsor
West Virginia University
NCT04065399 Phase 1, Phase 2
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rea...
Condition
Acute Myeloid Leukemia
Enrollment
447 pts
Location
United States, Australia, Canada
Sponsor
Syndax Pharmaceuticals
NCT07594522 Phase 1, Phase 2
Recruiting
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
Condition
Non-Small Cell Lung Cancer
Enrollment
36 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT06737731 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced ...
Condition
Malignant Solid Tumors
Enrollment
300 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT07617753 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Condition
Epithelial Ovarian Cancer
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
NCT07063875 Phase 1, Phase 2
Recruiting
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Condition
Uveal Melanoma
Enrollment
8 pts
Location
Australia
Sponsor
St Vincent's Hospital, Sydney
NCT06173219 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Mal...
Condition
Advanced Solid Tumor
Enrollment
38 pts
Location
China
Sponsor
China-Japan Friendship Hospita
NCT07447557 Phase 1, Phase 2
Recruiting
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
Condition
Charcot-Marie-Tooth Disease Type 4J
Enrollment
8 pts
Location
United States
Sponsor
Elpida Therapeutics SPC
NCT06873100 Phase 1, Phase 2
Recruiting
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Poly...
Condition
Relapsing Polychondritis
Enrollment
30 pts
Location
China
Sponsor
Peking University People's Hos
NCT07408232 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant...
Condition
Retinitis Pigmentosa
Enrollment
18 pts
Location
United States
Sponsor
Octant, Inc.
NCT04061421 Phase 1, Phase 2
Recruiting
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap...
Condition
MDS/MPN
Enrollment
94 pts
Location
United States
Sponsor
Michael Savona
NCT05919264 Phase 1, Phase 2
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Condition
Cancer
Enrollment
619 pts
Location
United States, Australia
Sponsor
Parabilis Medicines, Inc.
NCT06378593 Phase 1, Phase 2
Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With...
Condition
Solid Tumors With FGFR2 Alterations, Adult
Enrollment
130 pts
Location
China
Sponsor
3H (Suzhou) Pharmaceuticals Co
NCT07680595 Phase 1, Phase 2
Recruiting
Prospective Management of Plaque Instability With Statins and Extra Folic Acid
Condition
Carotid Atherosclerotic Plaque
Enrollment
180 pts
Location
China
Sponsor
Ruijin Hospital
NCT06657222 Phase 1, Phase 2
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Condition
Advanced Solid Tumors
Enrollment
250 pts
Location
United States, Canada, France
Sponsor
Gilead Sciences
NCT07242222 Phase 1, Phase 2
Recruiting
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
Condition
Fatty Liver
Enrollment
50 pts
Location
Egypt
Sponsor
Tanta University
NCT06287229 Phase 1, Phase 2
Recruiting
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene A...
Condition
Relapsed/Refractory
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05839275 Phase 1, Phase 2
Recruiting
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localize...
Condition
High-Risk Localized Soft Tissue Sarcoma
Enrollment
52 pts
Location
China
Sponsor
Fudan University
NCT04925609 Phase 1, Phase 2
Recruiting
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other So...
Condition
Anaplastic Large Cell Lymphoma, ALK-Positive
Enrollment
65 pts
Location
France, Netherlands
Sponsor
Princess Maxima Center for Ped
NCT04049539 Phase 1, Phase 2
Recruiting
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persis...
Condition
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Enrollment
28 pts
Location
United States
Sponsor
Ohio State University Comprehe
NCT06581419 Phase 1, Phase 2
Recruiting
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Maligna...
Condition
Advanced Malignant Neoplasm
Enrollment
78 pts
Location
China
Sponsor
SUNHO（China）BioPharmaceutical
NCT07284277 Phase 1, Phase 2
Recruiting
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Condition
Pancreatic Adenocarcinoma Metastatic
Enrollment
30 pts
Location
Spain
Sponsor
Clinica Universidad de Navarra
Page 1 of 16 — 384 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology